IHS Chemical Week

People & Business :: Earnings/Finance

Evogene raises $74 million in NYSE debut

8:26 AM MST | November 21, 2013 | Rebecca Coons

Shares of Evogene (Rehovot, Israel), a plant genomics firm in which both Monsanto and Bayer hold significant stakes, debuted on the New York Stock Exchange this morning at $14.75/share. The initial public offering raised approximately $74 million. Monsanto, which already held a 8.7% stake in Evogene, paid about $12 million to acquire 813,560 of the 5 million offered shares. Evogene says it has also granted the underwriters a 30-day option to purchase up to 750,000 additional ordinary shares at the same price per share. According to an F-1 filed in September...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa